Loading
GLAUKOS Corp Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 04 Jan 2016.
GLAUKOS Corp: what insiders have been doing
GLAUKOS Corp is a Healthcare & Pharma company. Its directors and officers file their transactions with SEC (Form 4). The last twelve months, up to 18 October 2026, brought 101 filings signed by 16 insiders.
No insider bought on the market over the period, while 3 insiders filed 28 sales totalling €17.2M. The amount is not disclosed for 1 filing. One trade stands out by size: a sale of €5.0M from Gilliam Joseph E, disclosed on 13 August 2026, or 0.063% of market capitalisation.
Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. The legal deadline for a Form 4 is two business days after the transaction. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify.
Compared with its exchange (5,810 companies, median 19 filings), a count of 101 filings is above the norm. Looking back to 2016, when coverage begins, insiders filed 2 purchases and 45 sales. The 10-K for the year ended 31 December 2025 shows 507.4 m USD of revenue and -187.7 m USD of net income.
Elsewhere in the same sector, our signals recently picked up insider purchases at Cooper Companies, Inc. and Anixa Biosciences Inc. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Insider Decl.
347
Thresholds
n/a
Buy Volume
n/a
2 ops. · all time
Sell Volume
€20M
45 ops. · all time
Who traded when
BuySaleTomas Navratil26 sales
Thurman Alex R.6 sales
Joseph E. Gilliam3 sales
Gilbert H. Kliman1 sale
Wen Leana1 sale
Since the insiders bought
- +37.5%Entry US$24.87 · Close at T+365 US$34.20
- +37.5%Entry US$24.87 · Close at T+365 US$34.20
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate GLAUKOS Corp Strong Buy (bullish), based on 13 analysts. Average price target: US$199.31.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 19,379 of 24,148 companies
30.7
score / 100
Value31
Quality31
FCF yld-0.4%
Earn yld-1.9%
EV/EBITDA·
ROE-26%
Gross mgn56%
Net mgn-37%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$167.89
Analyst consensus
13 analystsStrong buy
US$172.00Target US$199.31(+19%)US$225.00
Income statement
RevenueUS$507.4M
Gross profitUS$282.8M56% margin
EBITDA-US$146.1M-29% margin
Net income-US$187.7M-30.7% margin
Valuation
PER (forward)320.2x
P/Book14.5x
Beta0.70
Balance sheet & cash
Market capUS$9.9B
Total debtUS$103.9M
Free Cash Flow-US$39.1M
Debt / Equity16%
Profitability & ownership
ROE-26.0%
ROA-5.2%
% insiders3.6%
% institutions105.4%
Last declaration on 7 October 2026
Declarations347 total
888 shares@ US$163.930.0015% mcap1.3% of flowCommon StockSEC:0001193125-26-417151:0
327 shares@ US$164.780.0006% mcap0.5% of flowCommon StockSEC:0001193125-26-417151:1
312 shares@ US$165.600.0005% mcap0.5% of flowCommon StockSEC:0001193125-26-417151:2
1,527 shares@ US$164.4540.0026% mcap2.3% of flowCommonSEC144:0001959173-26-007271
1,083 shares@ US$154.880.0018% mcap1.6% of flowCommon StockSEC:0001920053-26-000030:3
136 shares@ US$152.710.0002% mcap0.2% of flowCommon StockSEC:0001920053-26-000030:1
167 shares@ US$151.700.0003% mcap0.2% of flowCommon StockSEC:0001920053-26-000030:0
229 shares@ US$154.240.0004% mcap0.3% of flowCommon StockSEC:0001920053-26-000030:2
1,615 shares@ US$154.27740.0028% mcap2.4% of flowCommonSEC144:0001959173-26-007117
460 shares@ US$167.320.0008% mcap0.7% of flowCommon StockSEC:0001920053-26-000028:3
234 shares@ US$170.950.0004% mcap0.4% of flowCommon StockSEC:0001920053-26-000028:5
103 shares@ US$163.200.0002% mcap0.2% of flowCommon StockSEC:0001920053-26-000028:0
345 shares@ US$164.600.0006% mcap0.5% of flowCommon StockSEC:0001920053-26-000028:1
191 shares@ US$166.200.0003% mcap0.3% of flowCommon StockSEC:0001920053-26-000028:2
120 shares@ US$168.380.0002% mcap0.2% of flowCommon StockSEC:0001920053-26-000028:4
4 shares@ US$172.000.0000% mcap0.0% of flowCommon StockSEC:0001920053-26-000028:6
1,457 shares@ US$166.92330.0027% mcap2.3% of flowCommonSEC144:0001959173-26-007014
6,091 shares@ US$181.190.012% mcap10.3% of flowCommon StockSEC:0001920053-26-000026:1
10 shares@ US$182.500.0000% mcap0.0% of flowCommon StockSEC:0001920053-26-000026:2
7,643 shares@ US$180.250.015% mcap12.9% of flowCommon StockSEC:0001920053-26-000026:0
13,744 shares@ US$180.66780.027% mcap23.3% of flowCommonSEC144:0001959173-26-006521
2,500 shares@ US$25.770.0007% mcap2.4% of flowCommon StockSEC:0001293171-26-000012:0
2,500 shares@ US$190.000.0052% mcap18.0% of flowCommonSEC144:0001959173-26-006238
10,000 shares@ US$48.460.0053% mcap1.2% of flowCommon StockSEC:0001705850-26-000022:0
20,000 shares@ US$55.180.012% mcap2.8% of flowCommon StockSEC:0001705850-26-000022:1
25 of 347 declarations
About GLAUKOS Corp
Glaukos Corp. (ticker: GKOS) is a United States-based ophthalmic medical technology and pharmaceutical company listed on the New York Stock Exchange (NYSE). Its global headquarters is in Aliso Viejo, California, United States. Founded in 1998, Glaukos has built its business around therapies for glaucoma, corneal disorders, and retinal diseases, positioning itself at the intersection of medical devices, procedural eye care, and ophthalmic pharmaceuticals. ([glaukos.com](https://www.glaukos.com/wp-content/uploads/2025/04/Glaukos-2024-Sustainability-Report-04162025-REVISED.pdf))
The company’s original breakthrough was in Micro-Invasive Glaucoma Surgery (MIGS), an alternative to the traditional glaucoma treatment paradigm. Glaukos launched its first MIGS device commercially in 2012, establishing an early and differentiated franchise in minimally invasive ophthalmic procedures. Over time, that innovation-led model broadened into a multi-platform strategy that combines devices, drug delivery, and corneal therapeutics rather than relying on a single product category. ([investors.glaukos.com](https://investors.glaukos.com/news/news-details/2025/Glaukos-to-Celebrate-10th-Anniversary-of-IPO-Listing-with-NYSE-Closing-Bell/default.aspx))
Read moreShow less
Today, Glaukos’ core commercial and development portfolio includes the iStent family for glaucoma, iDose TR, a long-duration intracameral drug-delivery platform for glaucoma, and Photrexa/Epioxa for corneal cross-linking in keratoconus. The company stated that iDose TR entered commercial launch activities in 2024, while Epioxa received FDA approval in October 2025 and became commercially available in March 2026. Glaukos also highlights a pipeline of follow-on programs and next-generation ophthalmic candidates, supporting the view that the business is still in a platform-expansion phase. ([sec.gov](https://www.sec.gov/Archives/edgar/data/0001192448/000110465926003321/gkos-20260113xex99d1.htm))
From a competitive standpoint, Glaukos occupies a strong niche in ophthalmology thanks to its proprietary technology, regulatory depth, and long-standing relationships with eye-care specialists. It is widely viewed as a category leader in MIGS and a meaningful innovator in corneal care. The company has a global commercial footprint, with direct operations in the United States, Canada, the United Kingdom, Germany, Japan, Australia, and Brazil, which helps diversify its revenue base beyond its home market. ([glaukos.com](https://www.glaukos.com/wp-content/uploads/2025/04/Glaukos-2024-Sustainability-Report-04162025-REVISED.pdf))
Recent developments have been particularly important. In January 2026, Glaukos reported preliminary full-year 2025 net sales of about $507 million, up roughly 32% year over year, and reiterated 2026 revenue guidance of $600 million to $620 million. The company also announced in September 2025 that it had broken ground on a new research, development, and manufacturing facility in Huntsville, Alabama, backed by an investment of more than $80 million, underlining its commitment to U.S. manufacturing capacity. In our view, these events reinforce the company’s transition from a single-franchise ophthalmology innovator into a broader, commercially scaled platform company. ([sec.gov](https://www.sec.gov/Archives/edgar/data/0001192448/000110465926003321/gkos-20260113xex99d1.htm))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
